RE:The value of revenue for Biotechs on the venture marketMMN...thanks for your conservative perspective on the stock price. One thing that everyone seems to be in agreement with is that upon reaching the milestones the price will continue to go up. All indications are that things are proceeding in an orderly fashion. What probably fascinates the shareholders the most is the potential of this stock both short and long term. You made a good point on the Canadian company Biosyent who's margins are similar to NPH and NPH having 6 times as many drugs at the moment. I am really looking forward to this story unfolding.